

Årsredovisning

för

NuVasive Sweden AB

559185-4079

Räkenskapsåret

2024

Fastställelseintyg

Undertecknad styrelseledamot i NuVasive Sweden AB intygar, dels att denna kopia av årsredovisningen stämmer överens med originalet, dels att resultaträkningen och balansräkningen i årsredovisningen har fastställts på årsstämma 02.07.2025. Årsstämman beslutade att godkänna styrelsens förslag till resultatdisposition.

Göteborg 15/7 2025



Mark Brian Alexander Lambert

2025071712173

NuVasive Sweden AB
Org.nr 559185-4079

1 (7)

Styrelsen för NuVasive Sweden AB avger följande årsredovisning för räkenskapsåret 2024.

Årsredovisningen är upprättad i euro, EUR. Om inte annat särskilt anges, redovisas alla belopp i hela euro (EUR). Uppgifter inom parentes avser föregående år.

Förvaltningsberättelse

Verksamheten

Allmänt om verksamheten

Företaget ska bedriva import, utveckling, produktion och försäljning av kirurgiska produkter, implantat och procedurellt integrerade lösningar för ryggraden. I allmänhet utförandet av alla typer av aktiviteter, operationer och tjänster som är naturliga för verksamheten för medicintekniska produkter. Liksom all annan handel, kommersiell eller privat och därmed förenlig verksamhet.

Företaget har sitt säte i Göteborgs Kommun.

Flerårsöversikt	2024	2023	2022	2021
Nettoomsättning	2 280	3 208	2 515	926
Resultat efter finansiella poster	1 519	1 892	1 433	331
Soliditet (%)	16,3	7,3	4,6	6,0

Förändringar i eget kapital

	Aktie- kapital	Balanserat resultat	Årets resultat	Totalt
Belopp vid årets ingång	4 789	105 484	100 565	210 838
Disposition enligt beslut av årsstämman:				
Balanseras i ny räkning		100 565	-100 565	0
Årets resultat			89 701	89 701
Belopp vid årets utgång	4 789	206 049	89 701	300 539

NuVasive Sweden AB
Org.nr 559185-4079

2 (7)

Resultatdisposition

Styrelsen föreslår att till förfogande stående vinstmedel (euro):

balanserad vinst	206 049
årets vinst	89 701
	295 750
disponeras så att	
i ny räkning överföres	295 750
	295 750

Företagets resultat och ställning i övrigt framgår av efterföljande resultat- och balansräkning med noter.

2025071712175

NuVasive Sweden AB
Org.nr 559185-4079

3 (7)

Resultaträkning

Not

2024-01-01
-2024-12-312023-01-01
-2023-12-31**Rörelseintäkter, lagerförändringar m. m.**

Nettoomsättning

2 279 943

3 208 053

Summa rörelseintäkter, lagerförändringar m.m.**2 279 943****3 208 053****Rörelsekostnader**

Handelsvaror

-343 793

-464 835

Övriga externa kostnader

-344 709

-894 809

Personalkostnader

1

0

0

Nedskrivning av omsättningstillgångar utöver normala nedskrivningar

0

-16 418

Summa rörelsekostnader**-688 502****-1 376 062****Rörelseresultat****1 591 441****1 831 991****Finansiella poster**

Valutakursdifferenser

-72 937

60 028

Summa finansiella poster**-72 937****60 028****Resultat efter finansiella poster****1 518 504****1 892 019****Bokslutsdispositioner**

Lämnade koncernbidrag

-1 428 803

-1 763 230

Summa bokslutsdispositioner**-1 428 803****-1 763 230****Resultat före skatt****89 701****128 789****Skatter**

Skatt på årets resultat

0

-28 224

Årets resultat**89 701****100 565**

2025071712176

NuVasive Sweden AB
Org.nr 559185-4079

4 (7)

Balansräkning

Not

2024-12-31

2023-12-31

TILLGÅNGAR**Omsättningstillgångar***Kortfristiga fordringar*

Kundfordringar

526 976

1 711 673

Övriga fordringar

73 381

190 575

Förutbetalda kostnader och upplupna intäkter

0

61 855

Summa kortfristiga fordringar**600 357****1 964 103***Kassa och bank*

Kassa och bank

1 242 534

941 745

Summa kassa och bank**1 242 534****941 745****Summa omsättningstillgångar****1 842 891****2 905 848****SUMMA TILLGÅNGAR****1 842 891****2 905 848**

2025071712177

NuVasive Sweden AB
Org.nr 559185-4079

5 (7)

Balansräkning

Not

2024-12-31

2023-12-31

EGET KAPITAL OCH SKULDER**Eget kapital***Bundet eget kapital*

Aktiekapital

4 789

4 789

Summa bundet eget kapital**4 789****4 789***Fritt eget kapital*

Balanserat resultat

206 049

105 483

Årets resultat

89 701

100 566

Summa fritt eget kapital**295 750****206 049****Summa eget kapital****300 539****210 838****Kortfristiga skulder**

Skulder till koncernföretag

1 468 254

2 484 843

Upplupna kostnader och förutbetalda intäkter

74 098

210 167

Summa kortfristiga skulder**1 542 352****2 695 010****SUMMA EGET KAPITAL OCH SKULDER****1 842 891****2 905 848**

2025071712178

NuVasive Sweden AB
Org.nr 559185-4079

6 (7)

Noter

Redovisningsprinciper

Allmänna upplysningar

Årsredovisningen är upprättad i enlighet med årsredovisningslagen och Bokföringsnämndens allmänna råd (BFNAR 2016:10) om årsredovisning i mindre företag.

Avskrivning

Tillämpade avskrivningstider:

Inventarier, verktyg och installationer 3

Nyckeltalsdefinitioner

Nettoomsättning

Rörelsens huvudintäkter, fakturerade kostnader, sidointäkter samt intäktskorrigeringar.

Resultat efter finansiella poster

Resultat efter finansiella intäkter och kostnader men före bokslutsdispositioner och skatter.

Soliditet (%)

Justerat eget kapital (eget kapital och obeskattade reserver med avdrag för uppskjuten skatt) i procent av balansomslutning.

Not 1 Medelantalet anställda

	2024	2023
Medelantalet anställda	0	0


2025071712179


NuVasive Sweden AB
Org.nr 559185-4079


7 (7)


Datum: 30.06.2025

2025071712180

DocuSigned by:

C2CC4F2763DF4EA...
Frédéric Claude G. Slock
Ordförande

DocuSigned by:

85A802D5FD71489...
Keith William Pfeil

DocuSigned by:

115FC87EB062441...
Mark Brian Alexander Lambert

DocuSigned by:

CC12A0EA29994AE...
Dustin S Shields

Certificate Of Completion

Envelope Id: 15F897E0-BDF6-4A5B-B1B4-37561BDA51D0
Subject: Complete with DocuSign: FS 2024 NuVasive Sweden AB 240101-241231 (002).pdf
Source Envelope:
Document Pages: 7
Certificate Pages: 5
AutoNav: Enabled
Envelopeld Stamping: Enabled
Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Status: Completed

Envelope Originator:
Rizki Ramin
7475 Lusk Blvd.
San Diego, CA 92121
rramin@nuvasive.com
IP Address: 62.45.67.101

Record Tracking

Status: Original
6/30/2025 2:29:26 AM

Holder: Rizki Ramin
rramin@nuvasive.com

Location: DocuSign

Signer Events

Dustin S Shields
dshields@globusmedical.com
SVP INTL Commercial
Security Level: Email, Account Authentication (None)

Signature

DocuSigned by:

CC12A0EA29994AE...


Signature Adoption: Drawn on Device
Using IP Address: 2a09:bac3:6540:78::c:3ac
Signed using mobile

Timestamp

Sent: 6/30/2025 2:32:54 AM
Viewed: 6/30/2025 7:00:37 AM
Signed: 6/30/2025 7:01:03 AM

Electronic Record and Signature Disclosure:
Accepted: 6/30/2025 7:00:37 AM
ID: 14352144-10ee-4f05-99af-f93b44d9d1be

Frederick Claude G. Slock
fslock@globusmedical.com
Security Level: Email, Account Authentication (None)


DocuSigned by:

C2CC4F2763DF4EA...

Signature Adoption: Drawn on Device
Using IP Address:
2001:ee0:40c1:fe3f:81c:a180:c534:c871
Signed using mobile

Sent: 6/30/2025 2:32:55 AM
Resent: 7/1/2025 12:18:48 AM
Resent: 7/1/2025 1:37:39 PM
Viewed: 7/2/2025 12:08:36 AM
Signed: 7/2/2025 12:09:43 AM

Electronic Record and Signature Disclosure:
Accepted: 7/2/2025 12:08:36 AM
ID: fc1e7b09-3de2-4078-8a0c-6db38e0754db

Keith William Pfeil
kpfeil@globusmedical.com
EVP, CFO/COO
Security Level: Email, Account Authentication (None)


DocuSigned by:

85A80205FD71489...

Signature Adoption: Pre-selected Style
Using IP Address: 85.190.233.192
Signed using mobile

Sent: 6/30/2025 2:32:55 AM
Viewed: 6/30/2025 3:24:14 AM
Signed: 6/30/2025 3:24:25 AM

Electronic Record and Signature Disclosure:
Accepted: 6/30/2025 3:24:14 AM
ID: ed52bc93-0fa5-43b5-82c9-e3c536ef0d1f

Mark Brian Alexander Lambert
mblambert@globusmedical.com
Security Level: Email, Account Authentication (None)

DocuSigned by:

115FC87EB062441...

Signature Adoption: Pre-selected Style
Using IP Address: 95.99.109.215

Sent: 6/30/2025 2:32:55 AM
Viewed: 6/30/2025 2:43:16 AM
Signed: 6/30/2025 2:43:28 AM

Electronic Record and Signature Disclosure:
Accepted: 6/30/2025 2:43:16 AM
ID: 8b883627-adfa-406f-b9b4-e16a64829bae

2025071712181

2025071712182

In Person Signer Events

Signature

Timestamp

Editor Delivery Events

Status

Timestamp

Agent Delivery Events

Status

Timestamp

Intermediary Delivery Events

Status

Timestamp

Certified Delivery Events

Status

Timestamp

Carbon Copy Events

Status

Timestamp

Artur Abramchenko
aabramchenko@globusmedical.com
Security Level: Email, Account Authentication (None)
Electronic Record and Signature Disclosure:
Accepted: 2/26/2025 4:15:27 AM
ID: d2c488ec-f5b4-4a9c-ba49-94d9abd7f85c

COPIED

Sent: 6/30/2025 2:32:56 AM

Denise Crawford
dcrawford@globusmedical.com
Security Level: Email, Account Authentication (None)
Electronic Record and Signature Disclosure:
Not Offered via DocuSign

COPIED

Sent: 6/30/2025 2:32:56 AM

Melissa Zamora
mzamora@globusmedical.com
Security Level: Email, Account Authentication (None)
Electronic Record and Signature Disclosure:
Accepted: 5/15/2024 12:07:39 PM
ID: 697e6b6c-46f1-4af5-a34b-e73a857765f8

COPIED

Sent: 6/30/2025 2:32:56 AM

Saulius Beresnevicius
sberesnevicius@globusmedical.com
Security Level: Email, Account Authentication (None)
Electronic Record and Signature Disclosure:
Accepted: 4/14/2025 7:55:26 AM
ID: 42b3f2e2-70fa-4e72-8add-3366fe578fb2

COPIED

Sent: 6/30/2025 2:32:56 AM

Witness Events

Signature

Timestamp

Notary Events

Signature

Timestamp

Envelope Summary Events

Status

Timestamps

Envelope Sent Hashed/Encrypted
Certified Delivered Security Checked
Signing Complete Security Checked
Completed Security Checked

6/30/2025 2:32:56 AM
6/30/2025 2:43:16 AM
6/30/2025 2:43:28 AM
7/2/2025 12:09:43 AM

Payment Events

Status

Timestamps

Electronic Record and Signature Disclosure

CONSUMER DISCLOSURE

From time to time, NuVasive, Inc (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign, Inc. (DocuSign) electronic signing system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to these terms and conditions, please confirm your agreement by clicking the "I agree"™ button at the bottom of this document.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after signing session and, if you elect to create a DocuSign signer account, you may access them for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. To indicate to us that you are changing your mind, you must withdraw your consent using the DocuSign "Withdraw Consent"™ form on the signing page of a DocuSign envelope instead of signing it. This will indicate to us that you have withdrawn your consent to receive required notices and disclosures electronically from us and you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures

2025071712183

electronically from us.

How to contact NuVasive, Inc:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: amekonen@nuvasive.com

To advise NuVasive, Inc of your new e-mail address

To let us know of a change in your e-mail address where we should send notices and disclosures electronically to you, you must send an email message to us at amekonen@nuvasive.com and in the body of such request you must state: your previous e-mail address, your new e-mail address. We do not require any other information from you to change your email address..

In addition, you must notify DocuSign, Inc. to arrange for your new email address to be reflected in your DocuSign account by following the process for changing e-mail in the DocuSign system.

To request paper copies from NuVasive, Inc

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an e-mail to amekonen@nuvasive.com and in the body of such request you must state your e-mail address, full name, US Postal address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with NuVasive, Inc

To inform us that you no longer want to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your DocuSign session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an e-mail to amekonen@nuvasive.com and in the body of such request you must state your e-mail, full name, US Postal Address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

Operating Systems:	Windows® 2000, Windows® XP, Windows Vista®; Mac OS® X
Browsers:	Final release versions of Internet Explorer® 6.0 or above (Windows only); Mozilla Firefox 2.0 or above (Windows and Mac); Safari®, 3.0 or above (Mac only)
PDF Reader:	Acrobat® or similar software may be required to view and print PDF files
Screen Resolution:	800 x 600 minimum
Enabled Security Settings:	Allow per session cookies

** These minimum requirements are subject to change. If these requirements change, you will be asked to re-accept the disclosure. Pre-release (e.g. beta) versions of operating systems and browsers are not supported.

Acknowledging your access and consent to receive materials electronically

2025071712185

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please verify that you were able to read this electronic disclosure and that you also were able to print on paper or electronically save this page for your future reference and access or that you were able to e-mail this disclosure and consent to an address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format on the terms and conditions described above, please let us know by clicking the "I agree"™ button below.

By checking the "I agree"™ box, I confirm that:

- I can access and read this Electronic CONSENT TO ELECTRONIC RECEIPT OF ELECTRONIC CONSUMER DISCLOSURES document; and
- I can print on paper the disclosure or save or send the disclosure to a place where I can print it, for future reference and access; and
- Until or unless I notify NuVasive, Inc as described above, I consent to receive from exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to me by NuVasive, Inc during the course of my relationship with you.